Cross-category comparison
Mounjaro vs Gastric Sleeve
Different categories, normalised only where comparison is meaningful.
Mounjaro
Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5
Sleeve gastrectomy
NHS/private UK sources commonly describe substantial total-body-weight loss; Imperial Private gives an approximate 25% body-weight figure as a practical anchor
How to use this comparison
Compare the factual differences below. We do not assign numerical treatment rankings: outcomes depend on the specific treatment, population, follow-up and your clinical circumstances.
Category-specific detail
| Issue | Mounjaro | Sleeve gastrectomy |
|---|---|---|
| Anatomical change | Not covered in this row | Around 80% of the stomach is removed, leaving a narrow sleeve |
| Diabetes / metabolic | Not covered in this row | Strong metabolic benefit, but bypass may be favoured in some diabetes/reflux contexts |
| Evidence anchor | Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5 | Not covered in this row |
| How it works | Dual GIP/GLP-1 receptor agonist | Not covered in this row |
| How taken | Weekly injection — Once weekly | Not covered in this row |
| Main trade-offs | Injection; GI side effects can be limiting; Access and NHS rollout are not the same as NICE eligibility; Ongoing treatment cost/maintenance matters if private | Not covered in this row |
| Maintenance | Long-term treatment may be needed; stopping can be followed by regain | Not covered in this row |
| NHS context | NICE-recommended; NHS access is phased / pathway-dependent | Common NHS bariatric procedure where specialist assessment supports it |
| Nutrition burden | Not covered in this row | Long-term vitamin/mineral supplementation and monitoring required |
| Procedure type | Not covered in this row | Laparoscopic surgery |
| Reflux | Not covered in this row | Can worsen or cause reflux in some people |
| Reversible | Not covered in this row | No |
| Revision | Not covered in this row | Can be converted/revised to bypass-type procedures when clinically appropriate |
| UK licence | UK weight management licence | Not covered in this row |
A detail omitted from one column is not evidence that it is irrelevant to that treatment. Use the full guides and discuss clinical suitability with your treating team.
Want support putting this into practice?
The Shift Programme is being built to combine evidence-led education, decision support, practical tools, progress tracking and long-term maintenance.
Sources & evidence
Check the underlying guidance directly: